Louisiana State Employees Retirement System Supernus Pharmaceuticals, Inc. Transaction History

Louisiana State Employees Retirement System

$5.21 Billion
Q4 2024

A detailed history of Louisiana State Employees Retirement System transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Louisiana State Employees Retirement System holds 26,700 shares of SUPN stock, worth $1.04 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

26,700

Previous 26,600 0.38%

Holding current value

$1.04 Million

Previous $829,000 16.41%

% of portfolio

0.02%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 29, 2025	BUY	$31.89 - $37.83 $3,189 - $3,783	100 Added 0.38%	26,700 $965,000
Q3 2024 Oct 23, 2024	SELL	$25.77 - $35.16 $28,347 - $38,675	-1,100 Reduced 3.97%	26,600 $829,000
Q2 2024 Jul 24, 2024	BUY	$25.99 - $33.85 $15,593 - $20,310	600 Added 2.21%	27,700 $740,000
Q1 2024 Apr 23, 2024	SELL	$27.11 - $35.17 $5,422 - $7,034	-200 Reduced 0.73%	27,100 $924,000
Q4 2023 Jan 29, 2024	SELL	$22.72 - $29.68 $11,360 - $14,840	-500 Reduced 1.8%	27,300 $790,000
Q3 2023 Oct 17, 2023	SELL	$27.57 - $32.91 $22,056 - $26,327	-800 Reduced 2.8%	27,800 $766,000
Q2 2023 Jul 18, 2023	BUY	$29.91 - $38.73 $101,694 - $131,682	3,400 Added 13.49%	28,600 $859,000
Q1 2023 Apr 19, 2023	SELL	$34.93 - $42.03 $17,465 - $21,015	-500 Reduced 1.95%	25,200 $912,000
Q4 2022 Jan 24, 2023	BUY	$31.09 - $37.88 $3,109 - $3,788	100 Added 0.39%	25,700 $917,000
Q3 2022 Oct 19, 2022	SELL	$28.79 - $35.41 $5,758 - $7,081	-200 Reduced 0.78%	25,600 $867,000
Q2 2022 Jul 20, 2022	SELL	$25.33 - $34.25 $2,533 - $3,425	-100 Reduced 0.39%	25,800 $773,000
Q1 2022 Apr 22, 2022	BUY	$28.51 - $32.9 $5,702 - $6,580	200 Added 0.78%	25,900 $768,000
Q4 2021 Jan 14, 2022	BUY	$26.37 - $34.22 $2,637 - $3,422	100 Added 0.39%	25,700 $749,000
Q3 2021 Oct 12, 2021	BUY	$23.54 - $31.39 $40,018 - $53,363	1,700 Added 7.11%	25,600 $683,000
Q2 2021 Jul 16, 2021	SELL	$26.72 - $33.19 $2,672 - $3,319	-100 Reduced 0.42%	23,900 $736,000
Q1 2021 Apr 14, 2021	SELL	$24.15 - $31.45 $7,245 - $9,435	-300 Reduced 1.23%	24,000 $628,000
Q4 2020 Jan 11, 2021	SELL	$17.7 - $25.81 $1,770 - $2,581	-100 Reduced 0.41%	24,300 $611,000
Q3 2020 Oct 19, 2020	BUY	$20.2 - $25.05 $203,818 - $252,754	10,090 Added 70.51%	24,400 $508,000
Q2 2020 Jul 13, 2020	SELL	$17.09 - $24.89 $3,418 - $4,978	-200 Reduced 1.38%	14,310 $340,000
Q1 2020 Apr 13, 2020	SELL	$14.45 - $24.69 $50,286 - $85,921	-3,480 Reduced 19.34%	14,510 $261,000
Q4 2019 Jan 17, 2020	SELL	$19.93 - $29.13 $28,101 - $41,073	-1,410 Reduced 7.27%	17,990 $427,000
Q3 2019 Oct 24, 2019	SELL	$25.47 - $33.37 $2,547 - $3,336	-100 Reduced 0.51%	19,400 $533,000
Q2 2019 Jul 15, 2019	SELL	$29.96 - $38.87 $2,996 - $3,886	-100 Reduced 0.51%	19,500 $622,000
Q1 2019 Apr 15, 2019	SELL	$32.77 - $41.99 $98 - $125	-3 Reduced 0.02%	19,600 $687,000
Q4 2018 Jan 14, 2019	SELL	$30.84 - $49.51 $104,763 - $168,185	-3,397 Reduced 14.77%	19,603 $651,000
Q3 2018 Oct 16, 2018	SELL	$42.7 - $56.55 $8,540 - $11,310	-200 Reduced 0.86%	23,000 $1.16 Million
Q2 2018 Jul 18, 2018	BUY	$44.1 - $59.85 $13,230 - $17,955	300 Added 1.31%	23,200 $1.39 Million
Q1 2018 Apr 18, 2018	BUY	$37.15 - $46.9 $29,720 - $37,520	800 Added 3.62%	22,900 $1.05 Million
Q4 2017 Jan 16, 2018	BUY	$36.4 - $42.6 $58,240 - $68,160	1,600 Added 7.8%	22,100 $881,000
Q3 2017 Oct 16, 2017	BUY	$36.75 - $49.65 $753,375 - $1.02 Million	20,500	20,500 $820,000

Others Institutions Holding SUPN

# of Institutions

302

Shares Held

60.6M

Call Options Held

25.2K

Put Options Held

2.6K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.09B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Louisiana State Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Louisiana State Employees Retirement System with notifications on news.

Account

Louisiana State Employees Retirement System Supernus Pharmaceuticals, Inc. Transaction History